- Report
- April 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- January 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- June 2025
- 400 Pages
Global
From €4349EUR$4,949USD£3,751GBP
- Report
- May 2024
- 137 Pages
Global
From €5710EUR$6,499USD£4,926GBP
Myobloc is a brand of botulinum toxin type B, a prescription medication used to treat certain musculoskeletal disorders. It is injected directly into the affected muscle to reduce spasms and improve movement. It is most commonly used to treat cervical dystonia, a condition that causes involuntary muscle contractions in the neck and shoulders. It is also used to treat other conditions such as blepharospasm, spasticity, and chronic migraine.
Myobloc is a relatively new drug, having been approved by the US Food and Drug Administration in 2000. It is the only botulinum toxin type B available in the US, and is the only one approved for use in the treatment of cervical dystonia.
The Myobloc market is a small but growing one, with a number of companies offering the drug. These include Allergan, Inc., Merz Pharmaceuticals, and Ipsen Biopharmaceuticals. Allergan is the largest producer of Myobloc, and is the only company to offer the drug in the US. Merz Pharmaceuticals and Ipsen Biopharmaceuticals both offer the drug in Europe. Show Less Read more